Malignant Pleural Mesothelioma: Current Understanding of the Immune Microenvironment and Treatments of a Rare Disease
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesothelioma is a rare disease with an annual incidence of around 3000 cases a year in the United States. Most cases are caused by asbestos exposure, with a latency period of up to 40 years. Pleural mesothelioma is an aggressive disease process with overall survival of roughly 6-12 months after the time of diagnosis. It is divided into three subtypes: epithelioid, mixed type, and sarcomatoid type, with the epithelioid subtype having the best overall survival. Often, the treatment is multimodality with surgery, chemotherapy, and radiation. The survival benefit is improved but remains marginal. New treatment options involving targeted immune therapies appear to offer some promise. The tumor microenvironment is the ecosystem within the tumor that interacts and influences the host immune system. Understanding this complex interaction and how the host immune system is involved in the progression of the disease process is important to define and guide potential treatment options for this devastating and rare disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, despite the novel and promising strategies targeting its TME, such as immunotherapy and the combination of immuno/chemotherapy, included in ongoing clinical trials on MPM, as recently reviewed in [8,26,148,149,150], the efficacy of these therapeutic approaches remains to be confirmed.”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · cited 3×
“chemotherapy, and delivery of radiation, the mean survival benefit for resectable disease remains marginal [2,3].”
BackgroundBaas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215 · cited 2×
“For example, the use of nivolumab and ipilimumab in other types of cancers such as melanoma, non-small-cell lung cancer, and renal cell carcinoma have shown promise in enhancing the antitumor function of T-cell responses and, when used in combination with traditional chemotherapy regimens, have shown a survival benefi…”
BackgroundMethodMechanisms in the Pathogenesis of Asbestosis and Silicosis
MOSSMAN, B. T., & CHURG, A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9707141 · Cited by 971 · cited 4×
“Microscopically, the disease process is defined by diffuse interstitial fibrosis and the presence of asbestos bodies [6,7].”
BackgroundInfluentialBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Maio, M., Scherpereel, A., Calabrò, L., Aerts, J., Perez, S. C., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 424 · cited 1×
“Given these findings, more work must be completed to fully elucidate the role of CTLA-4 inhibitors in patients with MPM [7,20].”
BackgroundPeters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.074 · Cited by 264
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole, S., Pritchard, A. L., Cebulla, C. M., Pilarski, R., Stautberg, M., Davidorf, F. H., de la Fouchardière, A., Cabaret, O., Golmard, L., Stoppa-Lyonnet, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy171 · Cited by 253
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 171
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone, M., Kanodia, S., Chao, A., Miller, A., Wali, A., Weissman, D., Adjei, A., Baumann, F., Boffetta, P., Buck, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.028 · Cited by 144
Pastorino, S., Yoshikawa, Y., Pass, H. I., Emi, M., Nasu, M., Pagano, I., Takinishi, Y., Yamamoto, R., Minaai, M., Hashimoto-Tamaoki, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0352 · Cited by 143
Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
Hegmans, J. P., Veltman, J. D., Lambers, M. E., de Vries, I. J. M., Figdor, C. G., W. Hendriks, R., Hoogsteden, H. C., Lambrecht, B. N., & Aerts, J. G. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1465oc · Cited by 141 · cited 2×
“Although this study did not show a survival benefit, it did demonstrate a host immune response to DC pulsed tumor lysate and may offer a potential therapy [19].”
BackgroundUjiie, H., Kadota, K., Nitadori, J.-I., Aerts, J. G., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., Krug, L. M., & Adusumilli, P. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009285 · Cited by 135 · cited 1×
“Furthermore, some evidence suggests that TAMs can upregulate IL-10 and B7-H3 on tumor cells, both of which are known to downregulate the immune response and inhibit antitumor T-cell responses [10,11].”
BackgroundCirculating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115 · cited 2×
“Furthermore, some evidence suggests that TAMs can upregulate IL-10 and B7-H3 on tumor cells, both of which are known to downregulate the immune response and inhibit antitumor T-cell responses [10,11].”
BackgroundThe Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
Treasure, T., Waller, D. A., Tan, C. H. C., Entwisle, J. J., O’Brien, M., O'Byrne, K. J., Thomas, G., Snee, M., Spicer, J. F., Landau, D., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ae26ae · Cited by 81
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70 · cited 2×
“malignant cells will adapt to the host immune environment and go on to further develop tumor variants that can circumvent the cytotoxic capabilities of the host immune system and eventually lead to tumor metastasis [7,9].”
BackgroundKiyotani, K., Park, J.-H., Inoue, H., Husain, A., Olugbile, S., Zewde, M., Nakamura, Y., & Vigneswaran, W. T. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1278330 · Cited by 69 · cited 1×
“This indicates a balance between immune cell activation and inhibition within the tumor microenvironment, and that once CD8+ TILs are activated and try to eradicate tumor cells, immune suppressive molecules and Tregs may respond and inadvertently assist cancer cells in escaping the host immune system [13].”
BackgroundSelf-citationSaddoughi, S. A., Abdelsattar, Z. M., & Blackmon, S. H. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.09.036 · Cited by 68
Shaikh, F., Zauderer, M. G., von Reibnitz, D., Wu, A. J.-C., Yorke, E. D., Foster, A., Shi, W., Zhang, Z., Adusumilli, P. S., Rosenzweig, K. E., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.026 · Cited by 64
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Kanteti, R., Dhanasingh, I., Kawada, I., Lennon, F. E., Arif, Q., Bueno, R., Hasina, R., Husain, A. N., Vigneswaran, W., Seiwert, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105919 · Cited by 57 · cited 3×
“For example, the use of nivolumab and ipilimumab in other types of cancers such as melanoma, non-small-cell lung cancer, and renal cell carcinoma have shown promise in enhancing the antitumor function of T-cell responses and, when used in combination with traditional chemotherapy regimens, have shown a survival benefi…”
BackgroundMethodSelf-citationGirolami, I., Lucenteforte, E., Eccher, A., Marletta, S., Brunelli, M., Graziano, P., Pisapia, P., Malapelle, U., Troncone, G., Scarpa, A., et al. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22509 · Cited by 56
Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., de Jong, S., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G. J. V., & Hegmans, J. P. J. J. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/798467 · Cited by 41 · cited 2×
“Therefore, the development of therapeutic targets on the IL-/IL-7R signaling axis may provide an attractive option for drug development [14].”
BackgroundResultErber, R., Warth, A., Muley, T., Hartmann, A., Herpel, E., & Agaimy, A. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000700 · Cited by 25
Frick, A. E., Nackaerts, K., Moons, J., Lievens, Y. N., Verbeken, E. K., Lambrecht, M. L. F., Coolen, J., Dooms, C., Vansteenkiste, J., Leyn, P. D., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy385 · Cited by 16
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma
Lee, H., Hamaji, M., Palivela, N., Jang, H.-J., Splawn, T. G., Ramos, D., Lee, A. K., Raghuram, A. C., Ramineni, M., Amos, C. I., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.10.031 · Cited by 9 · cited 1×
“tt t to harness the power and specificity of the immune system to recognize and destroy tumor cells and to prevent tumor recurrence [10,18,19].”
Background
Research works printed but not linked: 1
- Sugarbaker D. Bueno R. Burt B.M. Groth S.S. Loor G. Wolf A.S. Sugarbaker’s Adult Chest Surgery 3rd ed. McGraw Hill/Medical New York, NY, USA 2020
Cited by
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Zhao, Z., Li, J., Tan, F., Xue, Q., Gao, S., & He, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001900 · Cited by 18
Klotz, L. V., Zimmermann, J., Müller, K., Kovács, J., Hassan, M., Koller, M. T., Schmid, S., Huppertz, G., Markowiak, T., Passlick, B., et al. (2024) · Cancers · doi:10.3390/cancers16081587 · Cited by 14
Sørensen, J. B., Baas, P., Szépligeti, S. K., Pedersen, A. B., Johnsen, S. P., Carroll, R., Schoemaker, M. J., Rault, C., Daumont, M., & Ehrenstein, V. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.34802 · Cited by 7
“Malignant pleural mesothelioma (MPM) is a rare malignancy originating in the serosal cells of the pleura [1] with around 35,000 new cases and 30,000 deaths per year globally [2].”
BackgroundCramer, G. M., Davis, R. W., Papasavvas, E., Klampatsa, A., Miller, J. M., Carter, S. L., Ikpe, R., Yuan, M., Widura, S., Majumdar, R. S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0571 · Cited by 3
Metadata
- Authors
- Tedesco, J., Jaradeh, M., & Vigneswaran, W. T.
- Affiliations
- Loyola University Medical Center (US)
- Corresponding author
- Vigneswaran, Wickii T.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-11
- Volume
- 14
- Issue
- 18
- Pages
- 4415
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9496741
- OpenAlex
- W4295560430
- Cited by
- 12
- References
- 25
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 2
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- malignant pleural mesothelioma, tumor immune microenvironment, asbestos exposure, epithelioid subtype, multimodal therapy, chemotherapy, radiotherapy, rare tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.